Groundbreaking in the Nervonic Acid Field: Zhong Yuan Biotech Successfully Secures Two U.S. Patents

• Date：2023-10-17

• By：Zhong Yuan Biotech

On October 13, 2023 (October 12, US EST time), Zhong Yuan through its wholly owned subsidiary Bao Feng Biotechnology (Beijing) Ltd. received patent application of publication of the granted "Nervonic Acid" function in the United States. These two patents were successfully validated in the United States through the PCT route, with a primary focus on securing patent protection for future applications of nervonic acid molecules in IVD kits and pharmaceuticals.

Reportedly, Beijing Bao Feng has secured two authorized patents in the United States. One of these patents represents a pioneering revelation by publicly disclosing multiple nervonic acid molecules as biomarkers for cognitive impairments, including those related to Alzheimer's disease. The patent is titled "METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF," with the U.S. publication number US 2023/0324418 A1. The identification of nervonic acid molecules as biomarkers for cognitive impairments signifies their substantial potential for the development of diagnostic kits and pharmaceutical targets. Consequently, this patent safeguards Beijing Bao Feng’s exclusive legal rights for the global development of IVD kits and pharmaceuticals using the nervonic acid molecules identified within the patent.

The second patent is titled "METHOD FOR DIAGNOSING ACTIVITY OF NERVONIC ACID AND ITS USE," with the U.S. publication number US2023/0324419 A1. This patent safeguards a method for validating the effectiveness of nervonic acid in vivo. Beijing Bao Feng possesses a unique process for preparing and producing Acer truncatum seeds, from which nervonic acid, readily absorbable and transformable within the body, is extracted. This patent not only validates the efficacy of Beijing Bao Feng’s products but also unveils the enormous clinical potential of nervonic acid in the field of biopharmaceuticals. Simultaneously, it restricts third parties from using the methods and nervonic acid molecules mentioned in the patent for drug development, efficacy validation, or efficacy enhancement.

According to assessments provided by experts in the relevant industrial sector, these two patents from Beijing Bao Feng have established a strong foundation for the medical development of Acer truncatum and nervonic acid industries. They also offer comprehensive pharmaceutical protection for the medicinal applications of China's unique plant, Acer truncatum, and its nervonic acid extract, carrying substantial industrial value.